MilliporeSigma enters partnership with Oxford University’s Jenner Institute

 MilliporeSigma has entered a partnership with Oxford University’s Jenner Institute to develop more robust and scalable vaccine manufacturing processes. The partnership also aims to develop a vaccine manufacturing facility in Ghana.

“This collaboration with the Jenner Institute will facilitate access to affordable vaccines while improving the global response to disease outbreaks,” said Udit Batra, chief executive officer of MilliporeSigma. “MilliporeSigma is committed to expanding access to advanced drug therapies, especially in low- and middle-income countries. Together, with our partners, we have shaped how vaccine production is done today and are helping to solve the toughest problems of tomorrow.”

Through the collaboration with the Jenner Institute, the partners will improve the manufacturing process for adenovirus vaccines — vaccines based on adenovirus, a type of DNA virus, as a carrier — using MilliporeSigma products, systems and technologies on a real-world feed stream. By applying MilliporeSigma technology, the collaborators aim to develop a cost-effective and transferable manufacturing process that can be used to accelerate vaccine development and manufacturing worldwide.

Separately, MilliporeSigma is developing plans for a vaccine manufacturing facility in Ghana, helping to address significant health challenges in a continent that imports 99 percent of its vaccines. Working with Ridge Management Solutions and other partners, a recently signed memorandum of understanding between MilliporeSigma and Ridge provides the opportunity for Ghana to become the first country in Sub-Saharan Africa to have a dedicated human vaccine manufacturing factory.